Section Arrow
ALRN.NASDAQ
- Aileron Therapeutics
Quotes are at least 15-min delayed:2024/05/10 04:24 EDT
Last
 3.67
+0.02 (+0.55%)
Day High 
3.89 
Prev. Close
3.65 
1-M High
7.42 
Volume 
125.11K 
Bid
2.97
Ask
4.6
Day Low
3.28 
Open
3.55 
1-M Low
3.56 
Market Cap 
61.57M 
Currency USD 
P/E -- 
%Yield
10-SMA 4.25 
20-SMA 4.7 
50-SMA 5.29 
52-W High 7.42 
52-W Low 1.01 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.42/-4.40
Enterprise Value
61.57M
Balance Sheet
Book Value Per Share
0.41
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
JAGXJaguar Health0.3095+0.0421+15.74%-- 
DNAGinkgo Bioworks Holdings0.92+0.0266+2.98%-- 
CTMXCytomX Therapeutics2.04-2.15-51.31%-- 
GTHXG1 Therapeutics4.98+0.69+16.08%-- 
MCRBSeres Therapeutics1.02+0.2706+36.11%-- 
Quotes are at least 15-min delayed:2024/05/10 04:24 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development,LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.